No headlines found.
Globe Newswire (Tue, 10-Jan 8:00 AM ET)
Globe Newswire (Sun, 8-Jan 3:13 PM ET)
Globe Newswire (Wed, 23-Nov 8:00 AM ET)
Globe Newswire (Thu, 17-Nov 8:00 AM ET)
Globe Newswire (Wed, 9-Nov 8:00 AM ET)
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Absci trades on the NASDAQ stock market under the symbol ABSI.
As of February 3, 2023, ABSI stock price declined to $3.35 with 474,720 million shares trading.
ABSI has a beta of 2.09, meaning it tends to be more sensitive to market movements. ABSI has a correlation of 0.21 to the broad based SPY ETF.
ABSI has a market cap of $309.52 million. This is considered a Small Cap stock.
Last quarter Absci reported $2 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $499,000 and missed earnings estimates by -$.02.
The top ETF exchange traded funds that ABSI belongs to (by Net Assets): IWM, VTI, IWN, IBB, VXF.
ABSI stock has underperformed the market in the last year with a return of -51.9%, while SPY returned -6.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABSI shares. However, ABSI has outperformed the market in the last 3 month and 2 week periods, returning +13.2% and +24.5%, while SPY returned +11.6% and +4.2%, respectively. This indicates ABSI has been having a stronger performance recently.
ABSI support price is $3.15 and resistance is $3.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABSI stock will trade within this expected range on the day.